1. Generics Bulletin
  2. >>Leadership

Neuraxpharm Expands Into The Nordics With New Leader From Viatris

Company Plans To Make Its First Move With Buccolam

 
• By Akriti Seth

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Europe
Neuraxpharm has established a new business unit in Stockholm • Source: Alamy

Neuraxpharm has announced expanding into the Nordics with a new business unit covering the markets of Sweden, Norway, Finland, Denmark and Iceland. The central nervous system specialist has established Neuraxpharm Sweden in Stockholm and has appointed former Viatris executive Magnus Wassén to lead the new business unit as general manager of Neuraxpharm Nordics.

Through the business expansion and appointment of Wassén, Neuraxpharm said that it “now has both a strong platform and the necessary local expertise to launch new products

More from Leadership

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.